Literature DB >> 32076760

[A review of the update of the German S3-guideline on diagnostics and therapy of bipolar disorders 2019].

A Pfennig1, B Soltmann2, P Ritter2, T Bschor3, M Hautzinger4, T D Meyer5, F Padberg6, P Brieger7, M Schäfer8, C U Correll9, M Bauer2.   

Abstract

Since the first publication of the guideline in 2012, which included critically reviewed evidence up to 2010, several hundred articles with new evidence were published and some topics of the clinical consensus needed to be reconsidered. Therefore, it was urgently necessary to revise the guideline to bring them up to date. In this article important revisions and updates are presented and the chances and limitations of the development of the guidelines and their implementation are discussed.

Entities:  

Keywords:  Consensus; Evidence; Evidence-based psychiatry; Guidelines; Psychiatric care

Mesh：

Year:  2020        PMID： 32076760     DOI： 10.1007/s00115-020-00874-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


  16 in total

1.  Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial).

Authors:  Martin Lambert; Thomas Bock; Daniel Schöttle; Dietmar Golks; Klara Meister; Liz Rietschel; Alexandra Bussopulos; Marietta Frieling; Michael Schödlbauer; Marc Burlon; Christian G Huber; Gunda Ohm; Manoshi Pakrasi; Michael Sadre Chirazi-Stark; Dieter Naber; Benno G Schimmelmann
Journal:  J Clin Psychiatry       Date:  2010-03-23       Impact factor: 4.384

2.  Effect of Adjunctive Celecoxib on BDNF in Manic Patients Undergoing Electroconvulsive Therapy: a Randomized Double Blind Controlled Trial.

Authors:  M Kargar; A Yoosefi; S Akhondzadeh; V Artonian; A Ashouri; P Ghaeli
Journal:  Pharmacopsychiatry       Date:  2015-09-23       Impact factor: 5.788

3.  North of England evidence based guidelines development project: methods of guideline development.

Authors:  M Eccles; Z Clapp; J Grimshaw; P C Adams; B Higgins; I Purves; I Russell
Journal:  BMJ       Date:  1996-03-23

4.  Effectiveness of integrated care including therapeutic assertive community treatment in severe schizophrenia spectrum and bipolar I disorders: the 24-month follow-up ACCESS II study.

Authors:  Daniel Schöttle; Benno G Schimmelmann; Anne Karow; Friederike Ruppelt; Anne-Lena Sauerbier; Alexandra Bussopulos; Marietta Frieling; Dietmar Golks; Andrea Kerstan; Evangelia Nika; Michael Schödlbauer; Anne Daubmann; Karl Wegscheider; Matthias Lange; Gunda Ohm; Benjamin Lange; Christina Meigel-Schleiff; Dieter Naber; Klaus Wiedemann; Thomas Bock; Martin Lambert
Journal:  J Clin Psychiatry       Date:  2014-12       Impact factor: 4.384

5.  Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

Authors:  Carlos A Zarate; Nancy E Brutsche; Lobna Ibrahim; Jose Franco-Chaves; Nancy Diazgranados; Anibal Cravchik; Jessica Selter; Craig A Marquardt; Victoria Liberty; David A Luckenbaugh
Journal:  Biol Psychiatry       Date:  2012-01-31       Impact factor: 13.382

6.  The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients.

Authors:  Jules Angst; Rolf Adolfsson; Franco Benazzi; Alex Gamma; Elie Hantouche; Thomas D Meyer; Peter Skeppar; Eduard Vieta; Jan Scott
Journal:  J Affect Disord       Date:  2005-10       Impact factor: 4.839

7.  Electroconvulsive therapy is equally effective in unipolar and bipolar depression.

Authors:  S Bailine; M Fink; R Knapp; G Petrides; M M Husain; K Rasmussen; S Sampson; M Mueller; S M McClintock; K G Tobias; C H Kellner
Journal:  Acta Psychiatr Scand       Date:  2009-11-08       Impact factor: 6.392

8.  Selective publication of antidepressant trials and its influence on apparent efficacy.

Authors:  Erick H Turner; Annette M Matthews; Eftihia Linardatos; Robert A Tell; Robert Rosenthal
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245

9.  Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study.

Authors:  Carla Torrent; Caterina del Mar Bonnin; Anabel Martínez-Arán; Jesús Valle; Benedikt L Amann; Ana González-Pinto; José Manuel Crespo; Ángela Ibáñez; Mari Paz Garcia-Portilla; Rafael Tabarés-Seisdedos; Celso Arango; Francesc Colom; Brisa Solé; Isabella Pacchiarotti; Adriane R Rosa; Jose Luis Ayuso-Mateos; Celia Anaya; Patricia Fernández; Ramon Landín-Romero; Silvia Alonso-Lana; Jordi Ortiz-Gil; Bàrbara Segura; Sara Barbeito; Patricia Vega; Miryam Fernández; Amaia Ugarte; Marta Subirà; Ester Cerrillo; Núria Custal; José Manuel Menchón; Jerónimo Saiz-Ruiz; Jose Maria Rodao; Sandra Isella; Analucía Alegría; Susana Al-Halabi; Julio Bobes; Gonzalo Galván; Pilar A Saiz; Vicent Balanzá-Martínez; Gabriel Selva; Inmaculada Fuentes-Durá; Patricia Correa; María Mayoral; Guadalupe Chiclana; Jessica Merchan-Naranjo; Marta Rapado-Castro; Manel Salamero; Eduard Vieta
Journal:  Am J Psychiatry       Date:  2013-08       Impact factor: 18.112

10.  Effectiveness of integrated care including therapeutic assertive community treatment in severe schizophrenia-spectrum and bipolar I disorders: Four-year follow-up of the ACCESS II study.

Authors:  Daniel Schöttle; Benno G Schimmelmann; Friederike Ruppelt; Alexandra Bussopulos; Marietta Frieling; Evangelia Nika; Luise Antonia Nawara; Dietmar Golks; Andrea Kerstan; Matthias Lange; Michael Schödlbauer; Anne Daubmann; Karl Wegscheider; Anja Rohenkohl; Gizem Sarikaya; Mary Sengutta; Daniel Luedecke; Linus Wittmann; Gunda Ohm; Christina Meigel-Schleiff; Jürgen Gallinat; Klaus Wiedemann; Thomas Bock; Anne Karow; Martin Lambert
Journal:  PLoS One       Date:  2018-02-27       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.